Tagged with Lilly

China China’s pharma market is growing at an unprecedented pace and has become a key element of virtually all pharma multinationals’ international strategies. However, with a spate of regulatory reforms being rolled out, it can be challenging for large organizations with headquarters located in slower-paced mature markets to adapt to China’s…

Puerto Rico After climbing through the ranks from sales representative to leading business units at Eli Lilly Canada, François Gilbert took the reins of Eli Lilly’s Puerto Rican affiliate last year. Among other things, he shares the reasons why Eli Lilly invests in strong commercial capabilities and clinical operations on the island,…

Puerto Rico Victor Cruz, VP-Manufacturing Puerto Rico and Brazil for Lilly del Caribe highlights the priorities in his new position and underlines the importance of the Carolina facility for the global insulin supply. He also discusses Puerto Rico’s role related to future trends in pharmaceutical manufacturing, such as AI, robotics and continuous…

Puerto Rico Puerto Rico’s close-knit pharmaceutical sector is aiming to attract new talent to the industry so as to further increase its global competitiveness.   There is a strong, robust ecosystem around the pharmaceutical industry on the island and we are looking to attract the new generation to work in it Wendy…

Puerto Rico With more than 50 years of experience in pharmaceutical manufacturing, Puerto Rico is today a manufacturing base for 11 of the world’s 20 largest pharmaceutical and biopharmaceutical companies. However, considering its economic struggles and rising competition both from US states and international manufacturing hubs such as Ireland and Singapore, the…

China Julio Gay-Ger, an industry and Eli Lilly veteran, shares how he is leveraging on his 23 years of experience managing Lilly affiliates in LATAM to deliver on Lilly’s objective to position China as the second-largest affiliate for the Group; the significance of their recent February 2019 launch of diabetes treatment…

Spain Nabil Daoud, president of Lilly Spain, Portugal and Greece, highlights the importance of Lilly’s Spanish operations to the global group; Spain being the only country outside to hold manufacturing, pre-clinical research and commercial sales functionalities. Furthermore, he gives insight into his strategy to deliver the company’s exciting pipeline and his…

Korea Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market, emphasizing the importance of volume over price. He also concludes that Korea should focus on establishing itself as a leader…

Algeria Doria Oughlis, Lilly’s GM for North West Africa, outlines the company’s historic presence in Algeria, current priorities and Lilly’s overarching contribution to the health of the region.   Could you please start by describing Lilly’s legacy in Algeria to date? Lilly’s presence in Algeria actually long predates the setting up…

Algeria Multinational pharmaceutical companies are increasingly choosing Algeria as a base for their regional headquarters, despite the complexities of the local market. The representatives of Lilly, bioMérieux and Abbott in Algeria tell us why. As geographically the largest country in Africa, Algeria stands out, as does its universal healthcare system which bears…

Portugal Antonio Leão discusses Lilly Portugal’s sustained growth record in recent years, its ambition to introduce two new innovative treatments to the market every year until 2022, and their empowering approach when tackling market access hurdles. In suggesting improvements to the predictability of the pharmaceutical framework, Leão, soon to reach 30…

India Luca Visini, the recently appointed managing director of Eli Lilly & Company for India, shares with us his first perspective of the Indian ecosystem He also provides insights into some of his key objectives in India, which include consolidating the reputation of Eli Lilly as a key stakeholder in the…